Dokument: Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
| Titel: | Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107 | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=72974 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20260420-102006-6 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Schmitz, Jutta [Autor] Bartkowiak, Anna L. [Autor] Kolks, Nora [Autor] Petzsch, Patrick [Autor] Stoffel, Anne [Autor] Faßbender, Bianca [Autor] Lepping, Leandra [Autor] Volkamer, Julka [Autor] Köhrer, Karl [Autor] Seifert, Marc [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | PARP inhibitor , biomarker , BET inhibitor , Bladder cancer , combination therapy , epigenetics | |||||||
| Beschreibung: | Advanced urothelial carcinoma (UC) requires new therapeutics beyond chemo- and immunotherapies. Clinical trials with PARP inhibitors (PARPi), particularly in Cisplatin-treated UC, yielded limited response. Biomarker-based patient selection (apart from BRCAness) or combination treatment may increase efficacy. To identify the most suitable PARPi for UC, we compared Olaparib with Talazoparib. RNA sequencing of PARPi-treated UC lines revealed few common targets and a different impact on immune response. By analysis of experimental and public clinical data, we identified new UC-specific PARPi response predictors SLFN5, SLFN11, and OAS1. We investigated a new combination treatment using PLX51107, an epigenetic BET protein inhibitor, to increase PARPi efficacy. The Talazoparib + PLX51107 combination had a strong synergistic impact on UC cells and organoids, including Cisplatin-resistant cells, allowing dose reduction to spare benign cells. Mechanisms of synergism targeted homologous recombination repair, DNA replication, and apoptosis regulation. In conclusion, we suggest Talazoparib treatment of UC to be highly efficacious on all models examined when combined with PLX51107. This new combination treatment allows efficient application of PARPi Talazoparib to all UC patients, independent of Cisplatin pretreatment and genetic BRCAness. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Schmitz, J., Bartkowiak, A. L., Rose, M., Kolks, N., Petzsch, P., Solanki, V., Stoffel, A., Faßbender, B., Lepping, L., Volkamer, J., Köhrer, K., Seifert, M., Mahmoudi, T., Zuiverloon, T. C. M., Niegisch, G., & Hoffmann, M. J. (2025). Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. Molecular oncology, 20(3), 779–803. https://doi.org/10.1002/1878-0261.70148 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 20.04.2026 | |||||||
| Dateien geändert am: | 20.04.2026 |
